Characteristics Value patients (%) Sex   Male/Female 16/6 Age: median (range) at first Allo-HCT Age: median (range) at second Allo-HSCT 35 years (18-49) 37 years (20-49) Diagnosis N (%) Acute Myeloblastic Leukemia Chronic myeloid leukemia Acute lymphoblastic leukemia Medullary Aplasia Non Hodgkin lymphoma paroxysmal nocturnal hemoglobinuria  9 (41%) 5 (22%) 4 (18%) 2 (9%) 1 (5%) 1 (5%) Donor origin at the second Allo-HCT Same donor Other donor  14 (64%) 8 (36%) Cause of the second Allo-HCT Progression Graft Failure Graft failure and progression 14(64%) 6 (27%) 2 (9%) AML: Acute Myeloid Leukaemia; CR: Complete Remission; ALL: Acute Lymphoid Leukaemia; CML: Chronic Myeloid Leukaemia; TBI: Total Body Irradiation; GVHD: Graft-Versus-Host Disease; PBSC: Peripheral Blood Progenitor Cells; OS: Overall survival; DFS: Disease-Free Survival; M: Male; F: Female; T: Transplant; TRM: Transplant-Related Mortality

Table1: Patients Characteristics